Aurinia Pharmaceuticals: Down 30% From Its High, It Offers A Discounted De-Risked Multi-Billion Dollar Opportunity
Seeking Alpha,
Summary Aurinia’s voclosporin demonstrated exceptional Phase 3 trial results to treat Lupus Nephritis “LN”, a significant unmet…